期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素样肽1受体激动剂及二肽基肽酶4抑制剂在炎性疾病中的作用 被引量：2

Therapeutic effects of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor in inflammatory diseases
下载PDF
导出
摘要 胰高血糖素样肽1(glucagon like peptide-1,GLP-1)是主要由肠道L细胞分泌的一种肠促胰液素。GLP-1与GLP-1受体(glucagon like peptide-1 receptor,GLP-1R)结合后,通过促进胰岛β细胞增殖和分化、抑制胰岛β细胞的凋亡、刺激胰岛素合成和分泌、抑制胰高血糖素释放、降低食欲、抑制胃排空和增加饱腹感等多种机制降低血糖,维持体内血糖稳态。因此,近年来GLP-1和GLP-1R成为糖尿病治疗领域的研究热点。但是由于天然GLP-1极易被体内广泛分布的二肽基肽酶4(dipeptidyl peptidase-4,DPP-4)降解,因此目前在临床上广泛应用的以GLP-1R为靶点的新型降糖药物,主要是GLP-1R激动剂(glucagon like peptide-1 receptor agonists,GLP-1RAs)和DPP-4抑制剂。
作者 赵晴晴 潘昱 张一帆 ZHAO Qingqing;PAN Yu;ZHANG Yifan
机构地区 上海交通大学医学院附属瑞金医院核医学科
出处 《内科理论与实践》 2019年第6期381-385,共5页 Journal of Internal Medicine Concepts & Practice
关键词 胰高血糖素样肽1受体激动剂 二肽基肽酶4抑制剂 炎性疾病 抗炎作用
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献1

二级参考文献10

  • 1Lili Zhang,Mengliu Yang,Hong Ren,Huaidong Hu,Guenther Boden,Ling Li,Gangyi Yang.GLP ‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐ JNK[J].Liver Int.2013(5)
  • 2M. J. Armstrong,D. D. Houlihan,I. A. Rowe,W. H. O. Clausen,B. Elbr?nd,S. C. L. Gough,J. W. Tomlinson,P. N. Newsome.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program[J].Aliment Pharmacol Ther.2012(2)
  • 3A. de Souza Bruno,M. H. Rodrigues,M. C. B. Alvares,J. Nahas-Neto,E. A. Petri Nahas.Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women[J].Climacteric.2014(4)
  • 4Justin J. Wilkins,Michel Dubar,Bernard Sébastien,Christian Laveille.A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes[J].Journal of Clinical Pharmacology.2014(3)
  • 5Hui Chen,David Simar,Katherine Pegg,Sonia Saad,Clovis Palmer,Margaret J. Morris.Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents[J].Diabetologia.2014(3)
  • 6Yao Dai,Jawahar L. Mehta,Mingwei Chen.Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation[J].Cardiovascular Drugs and Therapy.2013(5)
  • 7N. D. Hopkins,D. J. Cuthbertson,G. J. Kemp,C. Pugh,D. J. Green,N. T. Cable,H. Jones.Effects of 6 months glucagon‐like peptide‐1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients[J].Diabetes Obes Metab.2013(8)
  • 8Christina Daousi,Jonathan H. Pinkney,Jacqueline Cleator,John P. Wilding,L.R. Ranganath.Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?[J].Regulatory Peptides.2013
  • 9Yuli Cai,Xiaorong Hu,Bo Yi,Ting Zhang,Zhongyuan Wen.Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression[J].Molecular Biology Reports.2012(12)
  • 10Nitika A. Gupta,Vasantha L. Kolachala,Rong Jiang,Carlos Abramowsky,Rene Romero,Nimita Fifadara,Frank Anania,Stuart Knechtle,Allan Kirk.The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis[J].The American Journal of Pathology.2012(5)

共引文献24

同被引文献24

引证文献2

二级引证文献8

内科理论与实践
2019年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部